NervGen Pharma (NGENF) Stock Price, News & Analysis

Company Overview

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company's lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage. The company was incorporated in 2017 and is based in Vancouver, Canada.

Key Stats

• Today's Range: $2.40 to $2.50
• 50-Day Range: $2.11 to $4.10
• 52-Week Range: $1.46 to $5.10
• Volume: 62,017 shs
• Average Volume: 137,678 shs
• Market Capitalization: $151.95 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Buy

NGENF Stock Analysis - Frequently Asked Questions

How have NGENF shares performed this year?

NervGen Pharma's stock was trading at $2.18 at the beginning of 2025. Since then, NGENF stock has increased by 12.8% and is now trading at $2.46.

How do I buy shares of NervGen Pharma?

Shares of NGENF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Today: 8/02/2025
• Next Earnings (Estimated): 8/20/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:NGENF
• CIK: N/A
• Web: N/A
• Phone: (778) 731-1711
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.07 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -73.14%
• Return on Assets: -56.59%

Debt

• Debt-to-Equity Ratio: 0.04
• Current Ratio: 11.21
• Quick Ratio: 11.21

Sales & Book Value

• Annual Sales: $150 thousand
• Price / Sales: 1,013.03
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 61,770,000
• Free Float: N/A
• Market Cap: $151.95 million
• Optionable: Not Optionable
• Beta: N/A